Collect the "World-famous character items" inside your smartphone
TOKYO, May 22, 2025 /PRNewswire/ -- Applibot, Inc. (Headquarters: Shibuya, Tokyo; President: Koki Ukita) is launching a new smartphone game app "Hello Kitty Merch Match", in 144 countries and regions worldwide this summer. Pre-registration for the game begins today, Thursday, May 22, 2025.
"Hello Kitty Merch Match" is a 3D puzzle game, offering simple, accessible gameplay where players find and tap on three matching character items. Over 1,000 different Sanrio character items appear in the game. Players of all ages can enjoy collecting and exploring this extensive virtual collection from nostalgic collectibles to the latest line ups.
Ahead of the game's official release, Applibot has launched the official website and social media accounts, alongside revealing the visual and concept movie for the title. "Hello Kitty Merch Match" is scheduled for release in summer 2025 across 144 countries and regions worldwide.
- Pre-Registration started!
Pre-registration is now available on both App Store and Google Play. By pre-registering, users will receive a notification when "Hello Kitty Merch Match" releases, with automatic download available within 24 hours of the release date. More information about "Hello Kitty Merch Match" will be announced via the official "Hello Kitty Merch Match" X (formerly Twitter) account and other channels.
*Note: The release date displayed on the App Store link is not the official release date.
*If the pre-order button (App Store) or pre-registration button (Google Play) is not active, please try accessing the page again later.
The visual and concept movie for "Hello Kitty Merch Match" have been unveiled for the first time. In both the visual and movie, various Sanrio characters visit the world of "Sanrio character items".
- Hello Kitty Merch Match Overview
-
- Title: Hello Kitty Merch Match
- Genre: 3D Match Puzzle
- Release Date: Summer 2025
- Price: Free to play (In-app purchases available)
- Supported OS: iOS/Android (Availability may vary depending on the device model)
- Developer and Operator: Applibot Inc.
- Copyright notice: © '25 SANRIO CO., LTD. APPR. NO. G650141 © Applibot, Inc.
ã€Official Links】
App Store: https://apps.apple.com/app/id6740388983
Google Play: https://play.google.com/store/apps/details?id=jp.co.applibot.HelloKittyMerchMatch
Official Website: https://hellokittymerchmatch.com/en
Official X (Twitter): https://x.com/HKMerchMatch
Concept Movie: https://www.youtube.com/watch?v=LRASLtEkQy8
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
"Hello Kitty Merch Match" Launching in 144 countries and regions worldwide in Summer 2025
"Hello Kitty Merch Match" Launching in 144 countries and regions worldwide in Summer 2025
"Hello Kitty Merch Match" Launching in 144 countries and regions worldwide in Summer 2025
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
